Table 1 Demographic characteristics at study entry
Characteristic | Mixed Motavizumab/Palivizumab (n = 83) | Mixed Palivizumab/Motavizumab (n = 84) | Motavizumab Only (n = 93) | Total (N = 260) |
|---|---|---|---|---|
Age, mo | ||||
Mean (SD) | 3.7 (3.1) | 3.4 (2.3) | 3.9 (2.4) | 3.7 (2.6) |
Gestational age at birth, wk | ||||
Mean (SD) | 31.0 (2.6) | 31.3 (2.9) | 30.9 (2.7) | 31.1 (2.7) |
Sex, n (%) | ||||
Male | 51 (61.4) | 43 (51.2) | 48 (51.6) | 142 (54.6) |
Race/ethnicity, n (%) | ||||
White/Non-Hispanic | 23 (27.7) | 20 (23.8) | 28 (30.1) | 71 (27.3) |
Hispanic | 53 (63.9) | 56 (66.7) | 57 (61.3) | 166 (63.8) |
Other | 7 (8.4) | 8 (9.5) | 8 (8.6) | 23 (8.8) |
Weight, kg | ||||
Mean (SD) | 4.6 (2.0) | 4.4 (1.8)a | 4.7 (1.7) | 4.6 (1.8) |
CLD present, n (%) | 11 (13.3) | 14 (16.7) | 16 (17.2) | 41 (15.8) |